Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 9trastuzumab deruxtecan 5trametinib 4dabrafenib 4zanubrutinib 3nilotinib 3fludarabine 3Trastuzumab 3Dexamethasone 3Cyclophosphamide 3tucatinib 2tisagenlecleucel 2selinexor 2relatlimab 2pemigatinib 2larotrectinib 2ipatasertib 2erdafitinib 2entrectinib 2enfortumab vedotin 2defactinib 2daratumumab 2blinatumomab 2binimetinib 2belzutifan 2axicabtagene ciloleucel 2atezolizumab 2TIC10 compound 2Sunitinib 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has announcements × glasdegib × Clear all
NCT01546038 2020-03-03

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Pfizer

Phase 2 Completed
255 enrolled 82 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡